Pharma

Jan 7 2018

To be niche players in neurology oncology: Eisai Pharma #drug #companies

#eisai pharma # While most Japanese drugmakers have been cautious post the Daiichi Sankyo’s crisis in Ranbaxy, Eisai Pharma is the only Japanese pharma company that continues to place its bet on the Indian pharma space. The company has consolidated its manufacturing and commercial operations in India and is adopting a multipronged growth strategy. The company which has been operating a Greenfield manufacturing facility in Vizag and is looking to grow its business in India. The plant currently caters entirely to the Japanese market. However Eisai wants to convert its India facility into a global sourcing hub that will export …

Dec 26 2017

Raptor Pharmaceutical (RPTP) Stock Slumps, Said to be Exploring Sale #shire #pharma

#raptor pharma # Raptor Pharmaceutical (RPTP) Stock Slumps, Said to be Exploring Sale NEW YORK (TheStreet ) — Shares of Raptor Pharmaceutical Corp. (RPTP ) are dipping by 5.85% to $5.47 on heavy trading volume Thursday afternoon, as the biopharmaceutical company is in talks with investment banks to hire a financial adviser to explore a possible sale, according to sources cited by Reuters after yesterday’s market close. The move may not lead to a sale, the sources added. JMP Securities upgraded the stock to “market outperform” from “market perform” and established a $9 price target following the report. A sale …

Dec 20 2017

Global pharmaceutical industry is in a strategic crisis – Business models must be adjusted #pharmaceutical #industry #overview #2013

#global pharmaceutical industry # Munich, January 06, 2013 Global pharmaceutical industry is in a strategic crisis – Business models must be adjusted Three out of four pharmaceutical companies are convinced their industry is in the midst of a strategic crisis Price and cost pressure, regulatory changes and expiring patents are leading to shrinking margins Emerging markets offer the biggest growth opportunities for the pharmaceutical industry – Their market share is set to rise to almost 40% by 2016, albeit with smaller margins Pharmaceutical companies are prepared to relocate their administration (44%), R D (43%) and sales departments (51%) to emerging …

Dec 2 2017

Raptor Pharmaceutical (RPTP) Stock Slumps, Said to be Exploring Sale #glide #pharma

#raptor pharma # Raptor Pharmaceutical (RPTP) Stock Slumps, Said to be Exploring Sale NEW YORK (TheStreet ) — Shares of Raptor Pharmaceutical Corp. (RPTP ) are dipping by 5.85% to $5.47 on heavy trading volume Thursday afternoon, as the biopharmaceutical company is in talks with investment banks to hire a financial adviser to explore a possible sale, according to sources cited by Reuters after yesterday’s market close. The move may not lead to a sale, the sources added. JMP Securities upgraded the stock to “market outperform” from “market perform” and established a $9 price target following the report. A sale …

Nov 30 2017

Why your #pharma #serialisation RFI should not be like Forrest Gump’s box of chocolates – full of surprises! #real #pharma

#forrest pharma # Why your #pharma #serialisation RFI should not be like Forrest Gump’s box of chocolates – full of surprises! Published March 1, 2016 As Forrest Gump s Momma could have said, An RFI is like box of chocolates you never know what s inside. Photo courtesy of Loren Javier Now that the EU-FMD clock has started ticking, pharma companies are compelled to take action. The first step for those in the pharma industry is often to generate a RFI for their serialization/traceability system. This is completely understandable when faced with the need to create a new and unfamiliar …

Nov 26 2017

Global pharmaceutical industry is in a strategic crisis – Business models must be adjusted #pharma #regulatory

#global pharmaceutical industry # Munich, January 06, 2013 Global pharmaceutical industry is in a strategic crisis – Business models must be adjusted Three out of four pharmaceutical companies are convinced their industry is in the midst of a strategic crisis Price and cost pressure, regulatory changes and expiring patents are leading to shrinking margins Emerging markets offer the biggest growth opportunities for the pharmaceutical industry – Their market share is set to rise to almost 40% by 2016, albeit with smaller margins Pharmaceutical companies are prepared to relocate their administration (44%), R D (43%) and sales departments (51%) to emerging …

Nov 23 2017

To be niche players in neurology oncology: Eisai Pharma #pharma #r&d

#eisai pharma # While most Japanese drugmakers have been cautious post the Daiichi Sankyo’s crisis in Ranbaxy, Eisai Pharma is the only Japanese pharma company that continues to place its bet on the Indian pharma space. The company has consolidated its manufacturing and commercial operations in India and is adopting a multipronged growth strategy. The company which has been operating a Greenfield manufacturing facility in Vizag and is looking to grow its business in India. The plant currently caters entirely to the Japanese market. However Eisai wants to convert its India facility into a global sourcing hub that will export …

Nov 16 2017

Global pharmaceutical industry is in a strategic crisis – Business models must be adjusted #pharmaceutical #market #analysis

#global pharmaceutical industry # Munich, January 06, 2013 Global pharmaceutical industry is in a strategic crisis – Business models must be adjusted Three out of four pharmaceutical companies are convinced their industry is in the midst of a strategic crisis Price and cost pressure, regulatory changes and expiring patents are leading to shrinking margins Emerging markets offer the biggest growth opportunities for the pharmaceutical industry – Their market share is set to rise to almost 40% by 2016, albeit with smaller margins Pharmaceutical companies are prepared to relocate their administration (44%), R D (43%) and sales departments (51%) to emerging …

Nov 14 2017

To be niche players in neurology oncology: Eisai Pharma #biotechnology #careers

#eisai pharma # While most Japanese drugmakers have been cautious post the Daiichi Sankyo’s crisis in Ranbaxy, Eisai Pharma is the only Japanese pharma company that continues to place its bet on the Indian pharma space. The company has consolidated its manufacturing and commercial operations in India and is adopting a multipronged growth strategy. The company which has been operating a Greenfield manufacturing facility in Vizag and is looking to grow its business in India. The plant currently caters entirely to the Japanese market. However Eisai wants to convert its India facility into a global sourcing hub that will export …

Nov 14 2017

Why your #pharma #serialisation RFI should not be like Forrest Gump’s box of chocolates – full of surprises! #pharmaceutical #careers

#forrest pharma # Why your #pharma #serialisation RFI should not be like Forrest Gump’s box of chocolates – full of surprises! Published March 1, 2016 As Forrest Gump s Momma could have said, An RFI is like box of chocolates you never know what s inside. Photo courtesy of Loren Javier Now that the EU-FMD clock has started ticking, pharma companies are compelled to take action. The first step for those in the pharma industry is often to generate a RFI for their serialization/traceability system. This is completely understandable when faced with the need to create a new and unfamiliar …